

- Wright DL, Anderson AC. Antifolate agents: a patent review (2006–2010). *Expert Opin Ther Pat* 2011;21:1293–1308.
- Chattopadhyay S, Moran RC, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. *Mol Cancer Ther* 2007;6:404–417.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003;21:2636–2644.
- Kindler HL. Systemic treatments for mesothelioma: standard and novel. *Curr Treat Options Oncol* 2008;9:171–179.
- Joerger M, Omlin A, Cerny T, et al. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. *Curr Drug Targets* 2010;11:37–47.
- Zain J, O'Connor O. Pralatrexate: basic understanding and clinical development. *Expert Opin Pharmacother* 2010;11:1705–1714.
- Sirotnak FM, DeGraw JI, Moccio DM, et al. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. *Cancer Chemother Pharmacol* 1984;12:18–25.
- O'Connor OA. Pralatrexate: an emerging new agent with activity in T-cell lymphomas. *Curr Opin Oncol* 2006;18:591–597.
- Bertino JR, Göker E, Gorlick R, et al. Resistance mechanisms to methotrexate in tumors. *Oncologist* 1996;1:223–226.
- Zhao R, Goldman ID. Resistance to antifolates. *Oncogene* 2003;22:7431–7457.
- Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. *Invest New Drugs* 2000;18:299–313.
- Saif MW, Ezzeldin H, Vance K, et al. DPYD*2A mutation: the most common mutation associated with DPD deficiency. *Cancer Chemother Pharmacol* 2007;60:503–507.
- Grem JL. Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer. *Oncology (Williston Park)* 2001;15:13–19.
- Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. *Expert Opin Drug Saf* 2009;8:191–202.
- Saif MW, Eloubeidi MA, Russo S, et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. *J Clin Oncol* 2005;23:8679–8687.
- Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med* 2006;355:2733–2743.
- Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. *Anticancer Drugs* 2008;19:447–464.
- Van Cutsem E, Verslype C, Tejpar S. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment. *Semin Oncol* 2005;32:43–51.
- Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. *J Clin Oncol* 2008;26:2118–2123.
- Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. *Expert Opin Investig Drugs* 2009;18:335–348.
- Saif MW, Rosen LS, Saito K, et al. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. *Anticancer Res* 2011;31:625–632.
- Daigo S, Takahashi Y, Fujieda M, et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. *Pharmacogenetics* 2002;12:299–306.
- Reiter A, Hochhaus A, Berger U, et al. AraC-based pharmacotherapy of chronic myeloid leukaemia. *Expert Opin Pharmacother* 2001;2:1129–1135.
- Braess J, Wegendt C, Feuring-Buske M, et al. Leukemic blasts differ from normal bone marrow mononuclear cells and CD34+ hematopoietic stem cells in their metabolism of cytosine arabinoside. *Br J Haematol* 1999;105:388–393.
- Momparler RL, Laliberte J, Eliopoulos N, et al. Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. *Anticancer Drugs* 1996;7:266–274.
- Cai J, Damaraju VL, Groulx N, et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. *Cancer Res* 2008;68:2349–2357.
- Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. *Cancer* 2006;107:116–124.
- Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. *Ann Oncol* 2006;17:v7–v12.
- Saif MW, Sellers S, Li M, et al. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. *Cancer Chemother Pharmacol* 2007;60:871–882.
- Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine). *Drug Resist Update* 2002;5:19–33.
- Saif MW, Lee Y, Kim R. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. *Ther Adv Med Oncol* 2012;4:341–346.
- Hong SP, Wen J, Bang S, et al. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. *Int J Cancer* 2009;125:2323–2331.
- Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2009;27:3778–3785.
- Hande KR. Purine antimetabolites. In: Chabner BA, Longo DL, eds. *Cancer Chemotherapy and Biotherapy: Principles and Practice*, 4th ed. Philadelphia: Lippincott-Raven; 2006: 212.
- Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. *Ther Drug Monitor* 2004;26:186–191.
- Wang L, Weinsilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges, and future directions. *Oncogene* 2006;25:1629–1638.
- Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. *Lancet* 2006;368:1339–1348.
- Montillo M, Ricci F, Tedeschi A. Role of fludarabine in hematological malignancies. *Expert Rev Anticancer Ther* 2006;6:1141–1161.
- Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. *Clin Pharmacokinet* 2002;41:93–103.
- van den Neste E, Cardoen S, Offner F, et al. Old and new insights into the mechanism of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine. *Int J Oncol* 2005;27:1113–1124.
- Gidron A, Tallman MS. 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. *Leuk Lymphoma* 2006;47:2301–2307.
- Huang P, Robertson LE, Wright S, et al. High molecular weight DNA fragmentation: a critical event in nucleoside analog-induced apoptosis in leukemia cells. *Clin Cancer Res* 1995;1:1005–1013.
- Grevz N, Saven A. Cladribine: from the bench to the bedside: focus on hairy cell leukemia. *Expert Rev Anticancer Ther* 2004;4:745–757.
- Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. *J Clin Invest* 1985;75:377–383.
- Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. *Nat Rev Drug Discov* 2006;5:855–863.
- Faderi S, Gandhi V, Keating MJ, et al. The role of clofarabine in hematologic and solid malignancies: development of a next generation nucleoside analog. *Cancer* 2005;102:1985–1995.
- Baytan B, Ozdemir O, Gunes AM, et al. Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia. *J Pediatr Hematol Oncol* 2010;32:144–146.